vs
EXPONENT INC（EXPO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是EXPONENT INC的1.2倍（$197.9M vs $166.3M），EXPONENT INC净利率更高（17.8% vs 6.7%，领先11.1%），EXPONENT INC同比增速更快（14.3% vs 13.6%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 8.8%）
Exponent Inc.是美国知名工程与科学咨询企业，汇集科学家、医师、工程师及商业咨询专家，可在90余个技术领域开展研究与分析工作，目前在美国本土设有20个办事处，境外另有5个办事网点。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EXPO vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.2倍
$166.3M
营收增速更快
EXPO
高出0.6%
13.6%
净利率更高
EXPO
高出11.1%
6.7%
两年增速更快
RGEN
近两年复合增速
8.8%
损益表 — Q1 FY2027 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $166.3M | $197.9M |
| 净利润 | $29.6M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 24.9% | 9.0% |
| 净利率 | 17.8% | 6.7% |
| 营收同比 | 14.3% | 13.6% |
| 净利润同比 | 11.0% | 143.9% |
| 每股收益（稀释后） | $0.59 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXPORGEN
| Q1 26 | $166.3M | — | ||
| Q4 25 | $147.1M | $197.9M | ||
| Q3 25 | $142.0M | $188.8M | ||
| Q2 25 | $145.5M | $182.4M | ||
| Q1 25 | $136.8M | $169.2M | ||
| Q4 24 | — | $174.1M | ||
| Q3 24 | $136.3M | $154.9M | ||
| Q2 24 | $140.5M | $154.1M |
净利润EXPORGEN
| Q1 26 | $29.6M | — | ||
| Q4 25 | $28.0M | $13.3M | ||
| Q3 25 | $26.6M | $14.9M | ||
| Q2 25 | $26.6M | $14.9M | ||
| Q1 25 | $23.6M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | $26.0M | $-654.0K | ||
| Q2 24 | $29.2M | $3.3M |
毛利率EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% |
营业利润率EXPORGEN
| Q1 26 | 24.9% | — | ||
| Q4 25 | 19.7% | 9.0% | ||
| Q3 25 | 12.1% | 8.9% | ||
| Q2 25 | 30.5% | 7.6% | ||
| Q1 25 | 19.9% | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | 19.0% | -5.1% | ||
| Q2 24 | 25.4% | 1.0% |
净利率EXPORGEN
| Q1 26 | 17.8% | — | ||
| Q4 25 | 19.1% | 6.7% | ||
| Q3 25 | 18.7% | 7.9% | ||
| Q2 25 | 18.3% | 8.2% | ||
| Q1 25 | 17.2% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | 19.1% | -0.4% | ||
| Q2 24 | 20.8% | 2.2% |
每股收益（稀释后）EXPORGEN
| Q1 26 | $0.59 | — | ||
| Q4 25 | $0.55 | $0.24 | ||
| Q3 25 | $0.52 | $0.26 | ||
| Q2 25 | $0.52 | $0.26 | ||
| Q1 25 | $0.45 | $0.10 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | $0.50 | $-0.01 | ||
| Q2 24 | $0.57 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $118.6M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $338.3M | $2.1B |
| 总资产 | $687.4M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EXPORGEN
| Q1 26 | $118.6M | — | ||
| Q4 25 | $207.4M | $767.6M | ||
| Q3 25 | $231.8M | $748.7M | ||
| Q2 25 | $245.1M | $708.9M | ||
| Q1 25 | $258.9M | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | $219.7M | $784.0M | ||
| Q2 24 | $203.3M | $809.1M |
总债务EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXPORGEN
| Q1 26 | $338.3M | — | ||
| Q4 25 | $402.9M | $2.1B | ||
| Q3 25 | $427.8M | $2.1B | ||
| Q2 25 | $441.4M | $2.1B | ||
| Q1 25 | $421.1M | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $410.3M | $2.0B | ||
| Q2 24 | $393.2M | $2.0B |
总资产EXPORGEN
| Q1 26 | $687.4M | — | ||
| Q4 25 | $761.4M | $2.9B | ||
| Q3 25 | $759.4M | $2.9B | ||
| Q2 25 | $763.2M | $2.9B | ||
| Q1 25 | $777.3M | $2.9B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | $744.1M | $2.8B | ||
| Q2 24 | $709.2M | $2.9B |
负债/权益比EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | $32.7M | $25.7M | ||
| Q3 25 | $36.2M | $48.1M | ||
| Q2 25 | $7.3M | $28.6M | ||
| Q1 25 | $56.1M | $15.0M | ||
| Q4 24 | — | $39.2M | ||
| Q3 24 | $29.7M | $49.3M | ||
| Q2 24 | $48.3M | $42.2M |
自由现金流EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | $30.0M | $17.6M | ||
| Q3 25 | $33.9M | $43.4M | ||
| Q2 25 | $5.5M | $21.5M | ||
| Q1 25 | $53.5M | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | $28.0M | $42.3M | ||
| Q2 24 | $47.2M | $37.4M |
自由现金流率EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | 20.4% | 8.9% | ||
| Q3 25 | 23.9% | 23.0% | ||
| Q2 25 | 3.8% | 11.8% | ||
| Q1 25 | 39.1% | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | 20.5% | 27.3% | ||
| Q2 24 | 33.6% | 24.3% |
资本支出强度EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 4.1% | ||
| Q3 25 | 1.6% | 2.5% | ||
| Q2 25 | 1.2% | 3.9% | ||
| Q1 25 | 1.9% | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 1.3% | 4.5% | ||
| Q2 24 | 0.8% | 3.1% |
现金转化率EXPORGEN
| Q1 26 | — | — | ||
| Q4 25 | 1.16× | 1.93× | ||
| Q3 25 | 1.36× | 3.23× | ||
| Q2 25 | 0.27× | 1.92× | ||
| Q1 25 | 2.38× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.65× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXPO
| Revenues before reimbursements | $151.8M | 91% |
| Reimbursements | $14.5M | 9% |
RGEN
暂无分部数据
